| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.13.12.1755 |
| P698 | PubMed publication ID | 8241095 |
| P2093 | author name string | P J Barter | |
| D R Sullivan | |||
| C Contacos | |||
| P433 | issue | 12 | |
| P921 | main subject | mixed hyperlipidemia | Q5150905 |
| lipid | Q11367 | ||
| P304 | page(s) | 1755-1762 | |
| P577 | publication date | 1993-12-01 | |
| P1433 | published in | Arteriosclerosis and thrombosis : a journal of vascular biology | Q27709770 |
| P1476 | title | Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia | |
| P478 | volume | 13 |
| Q28219488 | A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels |
| Q28362661 | An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia |
| Q34027325 | Combination drug therapy for combined hyperlipidemia |
| Q34107165 | Combination drug therapy for dyslipidemia. |
| Q35017838 | Combination therapy for combined dyslipidemia |
| Q33695135 | Dietary fatty acids and coronary heart disease |
| Q80059712 | Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects |
| Q36300191 | Effective use of combination lipid therapy |
| Q82456206 | Effective use of combination lipid therapy |
| Q34042886 | Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia |
| Q44346408 | Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia. |
| Q73873919 | Effects of ethyl-all-cis-5,8,11,14,17-icosapentaenoate (EPA-E), pravastatin and their combination on serum lipids and intimal thickening of cuff-sheathed carotid artery in rabbits |
| Q36071485 | Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction |
| Q98613627 | Efficacy and Safety of Prescription Omega-3 Fatty Acids Added to Stable Statin Therapy in Korean Patients with Type 2 Diabetes and Hypertriglyceridemia: a Randomized Controlled Trial |
| Q21245691 | Enhanced increase of omega-3 index in healthy individuals with response to 4-week n-3 fatty acid supplementation from krill oil versus fish oil |
| Q49795812 | Fatty acids modulate the expression levels of key proteins for cholesterol absorption in Caco-2 monolayer |
| Q35552231 | Fish oil for the treatment of cardiovascular disease. |
| Q35005057 | N-3 fatty acids and diabetes |
| Q61781878 | Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses |
| Q34018540 | Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. |
| Q80991553 | Omega-3 fatty acids alter lipoprotein subfraction distributions and the in vitro conversion of very low density lipoproteins to low density lipoproteins |
| Q30409882 | Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus |
| Q43874384 | Omega-3: a double-edged sword for autoimmune diseases |
| Q41348490 | Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease |
| Q34003407 | Preventing, stopping, or reversing coronary artery disease--triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: the need for recognition and treatment |
| Q53938520 | Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. |
| Q37701534 | Support of drug therapy using functional foods and dietary supplements: focus on statin therapy |
| Q54031637 | The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. |
| Q33569142 | The metabolic syndrome |
| Q36975868 | Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors |
| Q36661439 | n-3 Fatty acids and cardiovascular disease: actions and molecular mechanisms |
Search more.